sorafenib has been researched along with staurosporine in 53 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (staurosporine) | Trials (staurosporine) | Recent Studies (post-2010) (staurosporine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 416 | 0 | 286 |
| 6,520 | 730 | 5,251 | 6,272 | 58 | 976 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (15.09) | 29.6817 |
| 2010's | 31 (58.49) | 24.3611 |
| 2020's | 14 (26.42) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Getlik, M; Grütter, C; Klüter, S; Naqvi, T; Pawar, V; Rabiller, M; Rauh, D; Simard, JR | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Russu, WA; Shallal, HM | 1 |
| Hixon, MS; Hori, A; Imamura, S; Iwata, H; Kimura, H; Miki, H | 1 |
| Hah, JM; Kim, H; Kim, M; Lee, J; Yu, H | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Chen, Y; Chen, YZ; Chu, B; Gao, D; Jiang, Y; Jin, F; Liu, F; Tan, C; Zhang, C | 1 |
| Jia, Y; Wang, X; Wen, Q; Xu, F; Xu, W; Yang, K; Zhang, L; Zhang, Y | 1 |
| Chen, Y; Gao, D; Jiang, Y; Jin, F; Liu, F; Tan, C; Wu, Q | 1 |
| Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W | 1 |
| Wang, X; Wen, Q; Xu, F; Xu, H; Xu, W; Zhang, L; Zhang, Y | 1 |
| Aman, W; Hah, JM; Im, D; Jung, K; Yang, S | 1 |
| Abreu, RM; Calhelha, RC; Costa, R; Ferreira, IC; Froufe, HJ; Machado, VA; Peixoto, D; Queiroz, MJ; Soares, R | 1 |
| Cao, J; Li, X; Shen, Y; Shi, L; Wu, J; Zhou, H; Zhou, J | 1 |
| Ghosh, U; Kharkar, PS; Khedkar, VM; Kulkarni, MR; Kulkarni-Almeida, A; Lad, NP; Mane, MS; Pandit, SS; Sharma, R; Srivastava, A | 1 |
| Jia, S; Lei, H; Wang, C; Wang, M; Xiao, Z; Xu, S; Zheng, P; Zhi, J; Zhu, W | 1 |
| Chen, Y; Jiao, Y; Lu, T; Wang, L; Zhang, D; Zhang, Y | 1 |
| Abou-Zeid, LA; Ashour, HF; El-Sayed, MA; Selim, KB | 1 |
| Berger, BT; Chaikuad, A; Drápela, S; Knapp, S; Maier, L; Němec, V; Paruch, K; Souček, K | 1 |
| Abdelhamid, D; Abuo-Rahma, GEA; Badr, M; Hassan, A; Hassan, HA | 1 |
| Abdel-Maksoud, MS; Alach, NN; Anbar, HS; El-Gamal, MI; El-Gamal, R; Oh, CH; Sbenati, RM; Shehata, MK; Tarazi, H; Zaraei, SO | 1 |
| Chen, SS; Lee, HY; Lee, S; Liu, YT; Tai, HC; Tuan, YL; Wang, HH; Wang, SW; Yen, JY; Yu, CL | 1 |
| Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S | 1 |
| El-Subbagh, HI; Ghaly, MA; Maarouf, AR; Sabry, MA | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Bui, B; Italiano, A | 1 |
| Ehninger, G; Illmer, T | 1 |
| Aberg, E; Duyster, J; Engh, RA; Peschel, C; Sänger, J; von Bubnoff, N | 1 |
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Doki, Y; Hayashi, N; Hikita, H; Hosui, A; Ishida, H; Kodama, T; Miyagi, T; Mori, M; Nagano, H; Noda, T; Shimizu, S; Takehara, T; Tatsumi, T | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Cortes, J; Daver, N | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
| Abd El Razik, HA; Abu-Serie, MM; El-Miligy, MM | 1 |
| Perl, AE | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Bose, P; Cortes, JE; Dalle, IA; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, HM; Loghavi, S; Naqvi, K; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, N; Yalniz, F; Yilmaz, M | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Charlet, A; Döhner, K; Duyster, J; Endres, C; Fischer, T; Gorantla, SP; Haferlach, T; Heidel, FH; Meggendorfer, M; Rummelt, C; von Bubnoff, N | 1 |
| Amit, O; Avni, B; Bar-On, Y; Krayem, B; Pasvolsky, O; Peretz, G; Raanani, P; Ram, R; Rozovski, U; Shargian, L; Shimony, S; Wolach, O; Yeshurun, M; Zukerman, T | 1 |
| Abdelhamid, D; Abourehab, MAS; Abuo-Rahma, GEA; Badr, M; Hassan, A; Hassan, HA | 1 |
| Altman, JK; Chou, WC; Groß-Langenhoff, M; Hasabou, N; Hosono, N; Lee, JH; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Panoskaltsis, N; Perl, AE; Podoltsev, N; Recher, C; Röllig, C; Smith, CC; Strickland, S; Tiu, RV; Yokoyama, H | 1 |
10 review(s) available for sorafenib and staurosporine
| Article | Year |
|---|---|
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Molecular targeted therapy in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine | 2012 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
Availability of FLT3 inhibitors: how do we use them?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine | 2019 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
43 other study(ies) available for sorafenib and staurosporine
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Displacement assay for the detection of stabilizers of inactive kinase conformations.
Topics: Crystallography, X-Ray; Drug Design; Mitogen-Activated Protein Kinase 9; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Urea | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
Topics: Binding Sites; Cells, Cultured; Humans; Phosphorylation; Protein Kinase Inhibitors; Structure-Activity Relationship; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
Topics: Amides; Azepines; Cell Growth Processes; Cell Line, Tumor; Humans; Melanoma; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Pyrazoles; Structure-Activity Relationship; U937 Cells | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
Topics: Antineoplastic Agents; Benzopyrans; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Mitogen-Activated Protein Kinase 8; Models, Molecular; Molecular Structure; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth.
Topics: Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta, Thoracic; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; K562 Cells; Male; MCF-7 Cells; Models, Molecular; Molecular Structure; Neovascularization, Physiologic; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2013 |
Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Imatinib Mesylate; K562 Cells; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Niacinamide; Piperazines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; Pyrrolidines; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2013 |
Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III.
Topics: Angiogenesis Inhibitors; Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Male; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-akt; Purines; Rats; Rats, Sprague-Dawley; Sulfonamides | 2014 |
Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Structure-Activity Relationship; U937 Cells | 2015 |
Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors.
Topics: Angiogenesis Inhibitors; Apoptosis; Binding Sites; Cell Movement; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Molecular Docking Simulation; Neovascularization, Physiologic; Protein Structure, Tertiary; Structure-Activity Relationship; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neovascularization, Physiologic; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2016 |
Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors.
Topics: Antineoplastic Agents; Carbazoles; Drug Discovery; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Docking Simulation; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Structure-Activity Relationship | 2017 |
Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Structure-Activity Relationship | 2017 |
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Chalcones; Humans; Molecular Structure; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2020 |
Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
Topics: Animals; Carrier Proteins; Crystallography, X-Ray; Furans; Humans; MCF-7 Cells; Mice; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Structure-Activity Relationship | 2021 |
Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, ErbB-4; Structure-Activity Relationship; Thiazoles | 2021 |
Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Molecular Structure; Phenylurea Compounds; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship | 2022 |
New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Folic Acid Antagonists; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles | 2022 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
Topics: Animals; Benzenesulfonates; Cell Line; Drug Resistance; fms-Like Tyrosine Kinase 3; Indoles; Mice; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Receptors, Platelet-Derived Growth Factor; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2009 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cyclin G1; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sorafenib; Staurosporine; Up-Regulation | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
Midostaurin Gets FDA Nod for AML.
Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Staurosporine; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis.
Topics: Apoptosis; Binding Sites; Caspases; Cell Line, Tumor; Hep G2 Cells; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Piperazine; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Sorafenib; Staurosporine; Thiazolidines; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Remission Induction; Sorafenib; Staurosporine; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2019 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2021 |
Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Sorafenib; Staurosporine | 2021 |
Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
Topics: Adenocarcinoma; Amines; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Sorafenib; Staurosporine; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Sorafenib; Staurosporine | 2022 |